Financial Data and Key Metrics Changes - Revenue for Q2 2025 grew 3% to $10.85 billion, with adjusted operating income increasing 1% to $2.38 billion [7][28] - Adjusted operating margin was 21.9%, and adjusted EPS was $5.36 per share, exceeding guidance [7][19] - Year-to-date cash flow from operations was $2.1 billion, with free cash flow at $1.5 billion after net capital expenditures of $645 million [31] Performance by Business Segment - **Life Science Solutions**: Revenue increased 6% year-over-year, with organic growth at 4%. Adjusted operating income rose 6%, and adjusted operating margin was 36.8% [33] - **Analytical Instruments**: Revenue declined 3%, with organic growth down 4%. Adjusted operating income decreased 26%, and adjusted operating margin was 18.8% [34][35] - **Specialty Diagnostics**: Revenue grew 2% year-over-year, with organic revenue flat. Adjusted operating income increased 3%, and adjusted operating margin was 27% [36] - **Laboratory Products and Biopharma Services**: Revenue increased 4%, with organic growth at 3%. Adjusted operating income rose 11%, and adjusted operating margin was 13.8% [37] Market Data and Key Metrics Changes - In the pharma and biotech sector, mid-single-digit growth was achieved, driven by bioproduction and pharma services [8] - Academic and government revenue declined mid-single digits due to customer hesitancy [9] - Diagnostics and Healthcare revenue declined in the low single digits, impacted by challenges in China [10][28] Company Strategy and Industry Competition - The company focuses on three strategic pillars: high-impact innovation, trusted partner status, and a strong commercial engine [11] - Recent product launches include advanced mass spectrometers and a cryo transmission electron microscope, enhancing the company's competitive position [12][13] - The company is actively managing costs and leveraging its PPI business system to navigate tariff impacts and improve operational efficiency [18][41] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the long-term growth drivers of the industry, expecting a gradual improvement in end markets [20][23] - The company anticipates organic revenue growth of 3% to 6% in 2026 and 2027, with a long-term outlook of over 7% [21][24] - Management highlighted strong customer relationships and ongoing investments in innovation as key factors for future success [14][23] Other Important Information - The company announced the retirement of CFO Stephen Williamson, with Jim Meyer set to take over in March 2026 [48][50] - The acquisition of Silventum's purification and filtration business is on track to close by year-end [16] Q&A Session Summary Question: Long-term growth outlook and market share - Management provided clarity on the 7% long-term growth outlook, emphasizing strong conviction in industry drivers and share gains [55][60] Question: Margin expansion drivers - Margin expansion is expected to be driven by PPI business system tools and operational efficiencies, despite tariff impacts [62][66] Question: Biopharma investment trends - Management noted broad strength in biopharma, with strong growth in bioproduction and pharma services, indicating a positive outlook [70][72] Question: Analytical Instruments growth outlook - The segment is expected to face challenges due to muted conditions in academic and government sectors, but new product innovations are anticipated to drive share gains [76][86] Question: Reshoring impact - There is increased interest in expanding US manufacturing capacity, with no signs of customers pausing purchases in bioproduction [81][84] Question: Academic and government funding outlook - Bipartisan support for life sciences funding remains strong, with expectations for stabilization in academic and government budgets [98]